Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 167 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: etanercept Clear all
Withdrawn No phase listed Observational

Evaluation of Vitamin D Levels in Psoriasis Patients

NCT01903317
View directory record Official record
Conditions
Psoriasis
Interventions
Topical Therapy, Phototherapy and Systemic Therapy, Biologic Therapy
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)

NCT00259610
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
methotrexate, sulfasalazine, hydroxychloroquine, etanercept
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

NCT00205231
View directory record Official record
Conditions
HIV Infections
Interventions
etanercept
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

NCT01004432
View directory record Official record
Conditions
Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions
Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 2, 2026, 10:02 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

NCT03451851
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo for guselkumab, Etanercept
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset

NCT04254627
View directory record Official record
Conditions
Gulf War Illness
Interventions
Etanercept, Mifepristone
Drug
Lead sponsor
Nova Southeastern University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Davie, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

NCT00201838
View directory record Official record
Conditions
Pancreatic Neoplasms, Adenocarcinoma
Interventions
Gemcitabine, Etanercept
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

NCT00837434
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 2, 2026, 10:02 AM EDT
Recruiting Phase 1 Interventional

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

NCT03294954
View directory record Official record
Conditions
Neuroblastoma
Interventions
GINAKIT Cells, GINAKIT cells + Etanercept
Genetic · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2040
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 2, 2026, 10:02 AM EDT
Enrolling by invitation Early Phase 1 Interventional

RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

NCT05950724
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Etanercept Injection [Enbrel]
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

NCT00309907
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
etanercept, methylprednisolone
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

NCT02092467
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
tofacitinib, adalimumab, etanercept
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
4,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
142
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

NCT01860963
View directory record Official record
Conditions
Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions
Anal Pap smear and HPV DNA testing
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Treatments Against RA and Effect on FDG-PET/CT

NCT02374021
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 2, 2026, 10:02 AM EDT
Active, not recruiting No phase listed Observational

Psoriasis Longitudinal Assessment and Registry

NCT00508547
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20,167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
167
States / cities
Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

NCT02749370
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Scottsdale, Arizona • Beverly Hills, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

NCT00520572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD9056, Etanercept, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 2, 2026, 10:02 AM EDT
Not listed Phase 3 Interventional

The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis

NCT00012506
View directory record Official record
Conditions
Uveitis, Arthritis, Juvenile Rheumatoid
Interventions
TNFR:Fc
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

NCT00195494
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Methotrexate, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2012 · Synced Sep 2, 2026, 10:02 AM EDT
Completed No phase listed Observational Results available

Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project

NCT00116272
View directory record Official record
Conditions
Pregnancy
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 2, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

NCT00293202
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Kaysen, George A., M.D., Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 2, 2026, 10:02 AM EDT
Terminated Phase 2Phase 3 Interventional

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

NCT00127387
View directory record Official record
Conditions
Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions
Enbrel
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 2, 2026, 10:02 AM EDT
Not listed Phase 4 Interventional

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

NCT01132235
View directory record Official record
Conditions
Psoriasis
Interventions
etanercept
Biological
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Sep 2, 2026, 10:02 AM EDT